Drug profile

The FDA adverse-event record for Unspecified Ear Medication

27 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Ear Medication. Species, reactions, and outcomes follow.

#1540 of 2,679
by report volume (all drugs)
27
adverse-event reports
3.7%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Unspecified Ear Medication ranks #1516 of 2679 by total reports (27). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1516
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Unspecified Ear Medication has 27 reports now versus 27 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Unspecified Ear Medication changes

Signature read: Unspecified Ear Medication's 3.7% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
1
Deaths Reported
3.7%
Death-coded share of reports

Active Ingredients

Unspecified Ear Medication

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 15
Cat 12

Most Affected Breeds

Cat (unknown) 9
Retriever - Labrador 3
Maltese 2
Domestic Shorthair 2
Terrier - Yorkshire 2
Retriever - Golden 1
Domestic Longhair 1
Chihuahua 1
Terrier - Bull - American Pit 1
Shih Tzu 1

Most Reported Reactions

Behavioural disorder NOS 11
Pinnal erythema 10
Seizure NOS 4
Vomiting 3
Emesis (multiple) 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Ataxia 2
Loose stool 1
Emesis 1
Hair shedding 1
Application site hair loss 1
Excessive licking and/or grooming 1

Outcome Breakdown

Outcome Unknown
15 (55.6%)
Ongoing
6 (22.2%)
Recovered/Normal
5 (18.5%)
Died
1 (3.7%)

Unspecified Ear Medication: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Unspecified Ear Medication (#1540 of 2,679 by report volume); death-coded 3.7%. PlainBreed drug row · death-coded share stamp 3.7% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →